Have you been diagnosed with a B cell disease that has returned after your previous treatment or is not responding to your current treatment? If so, you might be able to take part in a study to see if a new treatment is safe and can help treat people with B-cell diseases.

The purpose of this research study is to learn more about the risk of severe and fatal infusion-related reactions (IRR) in patients with multiple myeloma who are treated with their first 3 administrations of daratumumab. Examples of severe IRR include lung tightness, low oxygen levels, difficulty breathing, high blood pressure, racing heart, headache, and too much fluid in the lungs. No fatal IRRs have been observed in clinical trials of daratumumab. We are also doing this study to help us to identify potential risk factors for IRR.

Do you have cervical cancer and are confused about health insurance or paying for your healthcare? We want to hear your thoughts on what might make it easier to navigate the financial side of cancer treatment. Your participation will help us to build a program to help cervical cancer patients like you. Compensation provided.

Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!

Have you been diagnosed with breast cancer? If so, you may be able to take part in a research study for the collection of tumor specimens and genomic DNA from patients with early or metastatic breast cancer.

Community-based interventions outside of North Carolina increase prostate cancer risk awareness and education among African Americans. Help us design an ideal intervention for/with communities in North Carolina. Your feedback and insight are instrumental in raising awareness and ultimately saving the lives of Black/African American men in North Carolina.

In this study, we want to learn if patients with advanced melanoma can stop treatment after 12 months of therapy.

Do you Patients with have Advanced Nasopharyngeal Carcinoma that has Progressed After Platinum Treatment and Immunotherapy? If so, you may be able to participate in a research study to find out if progression-free survival of the triplet combination (CaboNivoIpi) is more favorable than the doublet (NivoIpi).

Do you have multiple myeloma with MGRS-associated kidney disease? If so, you may be able to take part in a research study looking at the safety and effectiveness of a combination of medications for patients with multiple myeloma with MGRS-associated kidney disease.

Are you a premenopausal woman with hormone-positive breast cancer? If so, you may be able to participate in a study to learn if adding chemotherapy to the usual treatment improves survival and decreases the chances of cancer coming back.